Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Effective July 20,2023 Biostage Inc., BSTG, will change to Harvard Apparatus Regenerative Technology Inc., HRGN:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Has anything changed in the company at the moment?
Whole management team a bunch of scumbags. Mcgorry paying himself everyday for nothing and he screwed all those shareholders in 2017.
The technology deserves to be created but these guys deserve nothing.
Keep selling shares to china mcgorry as long as u and the team get paid right?
The mgmt is a bunch of liars. Their product failed in the only human test.
Need another $4 million this quarter mcgorry? How many shares outstanding now?
So they have 80 million authorized...current cash on hand will last a bit through third quarter this year...does anybody see a pattern here? They need 12 million a year to survive and they will probably continue diluting the company. On the conference call a few months back they couldn't even estimate how much they need once they file an IND.
Fan of the product...science...saving lives parts but do not like management's lack of clarity and aggressive dilution. Other stocks would be trading at 1 cent if they RS and intend to use all authorized while the shareholders get killed.
You are wrong. The fda gives them the run around. It's obvious. The fda are the cancer best friends. If you check the guidance the history of meeting from Hart to biostage under different management. The fact wiggle from mayo clinic didn't publish biostage work on animals in mayo peer magazine...The fda piss on them . It has nothing to do with the management
NO IND as expected. Such a good technology saves lives but dumb management!
Again....big sell orders in morning and then these small buys push it up to 3.74 from 3.00.
If nobody else sees what's going on with this stock it's scary.
Last trade 3.65! Up 14% with a larger than average volume.
Hope u are right. Just don't like these small buys. One large sell order and we are back into the 2s.
U have to decide market cap by 20. The one u see is wrong. There was 1:20 split and it's not updated yes to the market cap
Check the detailed quote on Ihub for market cap. They got $4 million from a share purchase that's dilution.
Check the detailed quote on Ihub for market cap. They got $4 million from a share purchase that's dilution.
Where did you find the market Cap info? What do you mean when you said "they diluted us"? Isn't it just a reverse-split?
Market cap is 118 million...they diluted us and will burn that 4 million quickly. What a bunch of BS and what happened with the lawsuit to go after Chip?
Still watching but won't buy anything until they prove to me that they can settle down.
Plus $36k in TRADES is nothing we have people on this board who can execute that in one trade.
They won't file any IND this year they would've done that if they could when Chip was around. Small buys are carrying this thing up and I am sick of it.
I agree it is good. But $100 worth of stock last summer is worth about $15 now. It was worth only $5 on 1/2/18. Still has a long way to go.
I WISH I bought 01/02, lol! I held even though it took a big dip because I felt like the price had gone too low. Fortunately I didn't sell and now the stock is on the upswing.
If you divide the current price by 20 you will get what the price would be without rs. Not a big increase. But at least an increase. If you held shares before the rs there was a fee for the reorganization of the stock from most online brokerages and most would be underwater from price decrease last fall. If you bought january 2nd then congrats.
Post split, on 01/02, it opened at 0.87. And since that date the price has more than tripled.
Yes, the effective pps dropped because of the market reaction to the reverse split. But my calculation was from the first day of year, not a time before that.
There was a 20 to 1 reverse split. The pre split increase is really .08 up to .15. Still good but the rs hurt.
BSTG has more than tripled in value since it closed at .87 on opening day of the new year.
This stock has doubled in value in the past 30 days.
Also, it appears to be the result of the new investment I mentioned in the stickied post.
This stock has been on the upswing! Based on SEC filings dating back to 01/10/2018 it looks like some new people have been investing in the company with big buys of the stock. Coincidentally, that's when the stock went on a tear. And it's up another 10% so far today!
What is up today?
Barchart.com has BSTGD as a buy!
https://www.barchart.com/stocks/quotes/BSTGD/overview
Bit of a gap 2.00-2.40 but hey, I'll take the last trade price at 2.40!
News! Chinese and hospital investors.
https://www.prnewswire.com/news-releases/biostage-closes-42-million-private-placement-300576750.html
Yikes. Another reverse split! What a pos this co is
Reverse Split Ratio 1:20 http://otce.finra.org/DailyList
1:20 R/S Tomorrow, per FINRA: http://otce.finra.org/DailyList
BSTGD
Great news! According to the most recent 10-Q, page 17, second to last paragraph: "The patient remains alive seven months after the surgery."
I think a girl named Claudia Castillo and a boy named Ciaran Finn Lynch are alive until today with a regenerated trachea made by biostage or similar tech as biostage . It's very interesting these 2 are alive with the implant . It was a partial success but again trachea was a challenge and was never tried in large animals . Look what happen now they neglected bronchus because probably large animals mean the pigs it didn't work well. I believe trachea wouldn't work well in pigs as well but the esophagus works. Anyway even the trachea was a partial success
The trachea implant worked partially. There was a regeneration but the new tissue lacked the ciliary cells . The absence of these cells caused the implant to fail overtime . In addition to that there was a doctor involved that many alleged was dishonest and he mislead probably all involved about the actual results.
I don't remember the company telling us about this:
On April 14, 2017, representatives for the estate of a deceased individual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company, Harvard Bioscience and other defendants. The complaint alleges that the decedent was harmed by two tracheal implants that incorporated synthetic trachea scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in two surgeries performed in 2012 and 2013, which harm caused her injury and death. The civil complaint seeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuit relates to the Company’s first generation trachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Cellframe technology nor to its lead development product candidate, the Cellspan esophageal implant. The litigation is at an early stage and the Company intends to vigorously defend this case. While the Company believes that such claim lacks merit, and has filed a motion seeking dismissal of the lawsuit, the Company is unable to predict the ultimate outcome of such litigation. In accordance with a separation and distribution agreement between Harvard Bioscience and the Company relating to the Separation, the Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer as a result of this litigation. The Company has been informed by its insurance provider that the case has been accepted as an insurable claim under the Company’s product liability insurance policy.
Agree 100%. Im just not personally a fan of reverse splits but they can be positive if pps stays up post split.
I'm not so sure a reverse split will suck. If they were faltering on the Nasdaq or NYSE and doing a reverse split in a desperate attempt to stay listed, then yeah -- I can see everyone abandoning and share price tanking.
But a reverse split will help them get back to the Nasdaq, which I think is what they're aiming for.
Another interesting point ... this company has successfully regenerated a human organ and yet this news is still flying under the radar. The penny stock enthustiasts haven't yet picked up or piled on to this one. Hopefully that will change before the RS.
I honestly think this thing gets wheels when deal is finalized. Reverse split kind of sucks but now could be the time to correct that for those who are averaged in at a higher PPS.
We shall see. today’s action is a continuation from yesterday’s PR.
That would be nice. BSTG!
That's good news! Up 34% right now!
4 mil in funding traded for .10 a share stock.
https://www.prnewswire.com/news-releases/biostage-announces-binding-agreement-for-40-million-private-placement-300571683.html
Looks like they got a lifeline. No BK in the near future. Looks like we might make a run back to .10 in the short term and possibly back up to previous PPS in the long term.
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1222
|
Created
|
03/04/14
|
Type
|
Free
|
Moderators |
Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company, develops and commercializes regenerated organs for human transplant. The company is developing the HART-Trachea, which includes a scaffold, the patient's cells, and a bioreactor to restore the structure and/or function of a severely damaged trachea; and automated solid organ bioreactor that has the ability to seed cells on an organ scaffold and keep them sterile and healthy during the growth phase prior to transplant. Its pre-clinical stage products include human-sized synthetic scaffold prototypes for esophageal transplant. Harvard Apparatus Regenerative Technology, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
http://investor.harvardapparatusregen.com/
84 October Hill Road, Suite 11
Holliston, MA 01746
1-774-233-7300
What Organs have been Regenerated?
The synthetic 3DTrachea will be the first commercial regenerated organ for transplant. HART is working with the leading regenerative medicine researchers and surgeons across the globe in their research involving a wide variety of organs. Materials that are used as an organ constructs are compatible with implantation into humans. Stem cells from the patient are introduced into the organ constructs and placed in a special bioreactor. The HARTbioreactors allow the growth of 3D organs with the same immunological characteristics as the host patient. Once this regenerative organ is in place, it is functionally and the medically correct for the specific host. Regenerated organs, unlike transplanted organs eliminate the need for expensive and harmful immuno suppressive drugs.
http://www.harvardapparatusregen.com/index.php/news-room/surgeries
InBreath Bioreactor Used in World's Second Successful Synthetic Trachea Transplant
Harvard Bioscience's Bioreactor Grows a Synthetic Tissue-Engineered Trachea Used in World's First Successful Human Transplantation
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |